Status:
NOT_YET_RECRUITING
Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens
Lead Sponsor:
Paolo Ghia
Conditions:
Chronic Lymphocytic Leukemia
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
CLL subjects who should receive treatment with a venetoclax-based regimen as per standard of care will be enrolled into this trial, after providing informed consent. The following evaluations will be...
Detailed Description
LN, PB and BM mononuclear cells collected from CLL patients at specified timepoints will be tested by: * High-throughput ex vivo drug assay (2D platforms) * Global transcriptome analysis by RNA seque...
Eligibility Criteria
Inclusion
- CLL diagnosis
- Patients receiving treatment with venetoclax-based regimens
- Baseline platelet value \>100x109/l
- PT INR and aPTT within normal range
Exclusion
- \- Patients receiving anticoagulant or antiplatelet treatment that cannot be safely interrupted before the biopsy
Key Trial Info
Start Date :
November 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04790045
Start Date
November 1 2023
End Date
December 31 2026
Last Update
October 3 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.